{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:37:44Z","timestamp":1793306264788,"version":"4.5.0"},"reference-count":69,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Dermatol Surg","DS"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND<\/jats:title>\n            <jats:p>Uncontrolled acute postoperative pain presents a significant management challenge when opioids are used in patients with end-stage renal disease (ESRD). Currently, there is a lack of quality pharmacokinetic and pharmacodynamic data regarding opioid medication use in ESRD patients to optimize safe and effective management.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OBJECTIVE<\/jats:title>\n            <jats:p>To review the published literature on pharmacologic evidence for and against the use of opioid medications for acute postoperative pain following Mohs micrographic surgery in ESRD patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS<\/jats:title>\n            <jats:p>A search of PubMed was conducted to identify articles on the pharmacokinetic and pharmacodynamic properties of opioid pain medications in ESRD patients through March 1, 2020.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>Seventy-five articles were reviewed. Limited data exist on opioids safe for use in ESRD and are mostly confined to small case series. Studies suggest tramadol and hydromorphone could be considered when indicated. Methadone may be a safe option, but should be reserved for treatment coordinated by a trained pain subspecialist.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>Randomized clinical trials are lacking. Studies that are available are not sufficient to perform a quantitative methodologic approach. Evidence supports the judicious use of postoperative opioid medications in ESRD patients at the lowest possible dose to achieve clinically meaningful improvement in pain and function.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/dss.0000000000002949","type":"journal-article","created":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T23:58:49Z","timestamp":1614383929000},"page":"454-461","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Narcotic Use for Acute Postoperative Pain Management in Mohs Micrographic Surgery Patients With End Stage Renal Disease: A Review of the Literature"],"prefix":"10.1097","volume":"47","author":[{"given":"Paul J.","family":"Gruber","sequence":"first","affiliation":[{"name":"Department of Dermatology, Dayton Skin Care Specialists, Dayton, Ohio;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaclyn M.","family":"Scholtz","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Resident Physician, Wright State University, Dayton, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi B.","family":"Donnelly","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Dayton Skin Care Specialists, Dayton, Ohio;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,2,22]]},"reference":[{"key":"R1-20250731","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMra1708701","article-title":"Update on keratinocyte carcinomas","volume":"379","author":"Nehal","year":"2018","journal-title":"N Engl J Med"},{"key":"R2-20250731","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1016\/j.ejca.2014.08.018","article-title":"Surgical excision versus Mohs' micrographic surgery for basal cell carcinoma of the face: a randomised clinical trial with 10 year follow-up","volume":"50","author":"Van Loo","year":"2014","journal-title":"Eur J Cancer"},{"key":"R3-20250731","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1111\/j.1524-4725.2011.02022.x","article-title":"A randomized controlled trial comparing acetaminophen, acetaminophen and ibuprofen, and acetaminophen and codeine for postoperative pain relief after Mohs surgery and cutaneous reconstruction","volume":"37","author":"Sniezek","year":"2011","journal-title":"Dermatol Surg"},{"key":"R4-20250731","first-page":"153","article-title":"Adult use of prescription opioid pain medications\u2014Utah, 2008","volume":"59","year":"2010","journal-title":"MMWR"},{"key":"R5-20250731","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6501e1","article-title":"CDC guideline for prescribing opioids for chronic pain\u2014United States, 2016","volume":"65","author":"Dowell","year":"2016","journal-title":"MMWR Recomm Rep"},{"key":"R6-20250731","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1097\/DSS.0000000000000073","article-title":"Opioid prescribing patterns after Mohs micrographic surgery and standard excision: a survey of American Society for Dermatologic Surgery members and a chart review at a single institution","volume":"40","author":"Harris","year":"2014","journal-title":"Dermatol Surg"},{"key":"R7-20250731","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1001\/jamadermatol.2013.1871","article-title":"Opioid pain medication use after dermatologic surgery: a prospective observational study of 212 dermatologic surgery patients","volume":"149","author":"Harris","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"Suppl 1","key":"R8-20250731","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"39","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"R9-20250731","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1681\/ASN.2015040373","article-title":"Variation in cancer incidence among patients with ESRD during kidney function and nonfunction intervals","volume":"27","author":"Yanik","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"R10-20250731","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1001\/jama.296.23.2823","article-title":"Cancer incidence before and after kidney transplantation","volume":"296","author":"Vajdic","year":"2006","journal-title":"JAMA"},{"key":"R11-20250731","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1001\/archderm.139.3.301","article-title":"Defining the clinical course of metastatic skin cancer in organ transplant recipients: a multicenter collaborative study","volume":"139","author":"Martinez","year":"2003","journal-title":"Arch Dermatol"},{"key":"R12-20250731","first-page":"2","article-title":"Wound healing in patients with impaired kidney function","volume":"5","author":"Maroz","year":"2014","journal-title":"J Am Coll Clin Wound Spec"},{"key":"R13-20250731","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ackd.2005.03.008","article-title":"Chronic pain in end-stage renal disease","volume":"12","author":"Davison","year":"2005","journal-title":"Adv Chronic Kidney Dis"},{"key":"R14-20250731","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.jpainsymman.2005.05.013","article-title":"The impact of chronic pain on depression, sleep, and the desire to withdraw from dialysis in hemodialysis patients","volume":"30","author":"Davison","year":"2005","journal-title":"J Pain Symptom Manage"},{"key":"R15-20250731","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.2215\/CJN.00220114","article-title":"Associations of depressive symptoms and pain with dialysis adherence, health resource utilization, and mortality in patients receiving chronic hemodialysis","volume":"2014","author":"Weisbord","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"R16-20250731","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1681\/ASN.2017010098","article-title":"Opioid prescription, morbidity, and mortality in United States dialysis patients","volume":"28","author":"Kimmel","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"R17-20250731","doi-asserted-by":"crossref","first-page":"746","DOI":"10.2215\/CJN.09910917","article-title":"Opioid analgesics and adverse outcomes among hemodialysis patients","author":"Ishida","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"R18-20250731","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/dsu.12166","article-title":"Assessment of postoperative pain after Mohs micrographic surgery","volume":"39","author":"Limthongkul","year":"2013","journal-title":"Dermatol Surg"},{"key":"R19-20250731","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.jaad.2012.05.041","article-title":"The safety of Mohs surgery: a prospective multicenter cohort study","volume":"67","author":"Merritt","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"R20-20250731","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1053\/j.ajkd.2003.08.025","article-title":"Pain in hemodialysis patients: prevalence, etiology, severity, and management","volume":"42","author":"Davison","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"R21-20250731","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1111\/j.1523-1755.2004.00658.x","article-title":"Analgesic prescription patterns among hemodialysis patients in the DOPPS: potential for underprescription","volume":"65","author":"Baile","year":"2004","journal-title":"Kidney Int"},{"key":"R23-20250731","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2215\/CJN.05180418","article-title":"Clinical pharmacology considerations in pain management in patients with advanced kidney failure","volume":"14","author":"Davison","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"R24-20250731","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/sdi.12196","article-title":"Pain in chronic kidney disease: a scoping review","volume":"27","author":"Davison","year":"2014","journal-title":"Semin Dial"},{"key":"R27-20250731","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/j.1552-4604.1980.tb01692.x","article-title":"Clinical effects of parenteral narcotics in hospitalized medical patients","volume":"20","author":"Miller","year":"1980","journal-title":"J Clin Pharmacol"},{"key":"R28-20250731","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1097\/00000542-197506000-00021","article-title":"Narcotic analgesics in anuric patients","volume":"42","author":"Don","year":"1975","journal-title":"Anesthesiology"},{"key":"R29-20250731","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/clpt.1993.127","article-title":"The pharmacokinetics of morphine and morphine glucuronides in kidney failure","volume":"54","author":"Osborne","year":"1993","journal-title":"Clin Pharmacol Ther"},{"key":"R32-20250731","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0376-8716(99)00041-1","article-title":"A postmarketing surveillance program to monitor Ultram (tramadol hydrochloride) abuse in the United States","volume":"57","author":"Cicero","year":"1999","journal-title":"Drug Alcohol Depend"},{"key":"R33-20250731","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2165\/00003495-199346020-00008","article-title":"Tramadol: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute and chronic pain states","volume":"46","author":"Lee","year":"1993","journal-title":"Drugs"},{"key":"R34-20250731","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1159\/000064092","article-title":"Pharmacokinetics of tramadol in a hemodialysis patient","volume":"92","author":"Izzedine","year":"2002","journal-title":"Nephron"},{"key":"R35-20250731","doi-asserted-by":"crossref","first-page":"6","DOI":"10.4103\/0970-9185.150518","article-title":"Postoperative pain management in patients with chronic kidney disease","volume":"31","author":"Tawfic","year":"2015","journal-title":"J Anaesthesiol Clin Pharmacol"},{"key":"R36-20250731","doi-asserted-by":"crossref","first-page":"21","DOI":"10.18773\/austprescr.2016.008","article-title":"Prescribing for patients on dialysis","volume":"39","author":"Smyth","year":"2016","journal-title":"Aust Prescr"},{"key":"R37-20250731","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2165\/00003088-200443130-00004","article-title":"Clinical pharmacology of tramadol","volume":"43","author":"Grond","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"R38-20250731","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0272-6386(03)00645-0","article-title":"Analgesia in patients with ESRD: a review of available evidence","volume":"42","author":"Kurella","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"R39-20250731","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/bdd.2510130607","article-title":"Pharmacokinetics and metabolism of codeine in humans","volume":"13","author":"Vree","year":"1992","journal-title":"Biopharm Drug Disposition"},{"key":"R40-20250731","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/clpt.1988.12","article-title":"Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease","volume":"43","author":"Guay","year":"1988","journal-title":"Clin Pharmacol Ther"},{"key":"R41-20250731","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/j.1365-2044.1992.tb03145.x","article-title":"Profound hypotension following intravenous codeine phosphate. Three case reports and some recommendations","volume":"47","author":"Parke","year":"1992","journal-title":"Anaesthesia"},{"key":"R42-20250731","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/000992289703600308","article-title":"Respiratory arrest precipitated by codeine in a child with chronic renal failure","volume":"36","author":"Talbott","year":"1997","journal-title":"Clin Pediatr (Phila)"},{"key":"R43-20250731","first-page":"15","article-title":"Codeine dosage in renal failure","volume":"5","author":"Matzke","year":"1986","journal-title":"Clin Pharm"},{"key":"R44-20250731","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1179\/096992603225002627","article-title":"Palliation and chronic renal failure: opioid and other palliative medications\u2013Dosage guidelines","volume":"11","author":"Broadbent","year":"2003","journal-title":"Prog Palliat Care"},{"key":"R45-20250731","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/cpdd.238","article-title":"Effects of renal impairment and hepatic impairment on the pharmacokinetics of hydrocodone after administration of a hydrocodone extended-release tablet formulated with abuse-deterrence technology","volume":"5","author":"Darwish","year":"2016","journal-title":"Clin Pharmacol Drug Dev"},{"key":"R46-20250731","first-page":"335","article-title":"Pain management in chronic kidney disease: the pharmacokinetics and pharmacodynamics of hydromorphoneand hydromorphone-3-glucuronide in hemodialysis patients","volume":"4","author":"Davison","year":"2008","journal-title":"J Opioid Manag"},{"key":"R47-20250731","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1016\/j.pain.2013.08.015","article-title":"Intradialytic clearance of opioids: methadone versus hydromorphone","volume":"154","author":"Perlman","year":"2013","journal-title":"Pain"},{"key":"R48-20250731","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1191\/026921601669626431","article-title":"Retrospective study of the use of hydromorphone in palliative care patients with normal and abnormal urea and creatinine","volume":"15","author":"Lee","year":"2001","journal-title":"Palliat Med"},{"key":"R49-20250731","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0376-8716(80)90180-5","article-title":"Methadone use in patients with chronic renal disease","volume":"5","author":"Kreek","year":"1980","journal-title":"Drug Alcohol Depend"},{"key":"R50-20250731","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/ndt\/14.1.254","article-title":"Methadone is poorly removed by haemodialysis","volume":"14","author":"Furlan","year":"1999","journal-title":"Nephrol Dial Transpl"},{"key":"R51-20250731","first-page":"CD003971","article-title":"Methadone for cancer pain","author":"Nicholson","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"R52-20250731","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.jpainsymman.2016.05.022","article-title":"Efficacy and safety of two methadone titration methods for the treatment of cancer-related pain: the EQUIMETH2 trial (methadone for cancer-related pain)","volume":"52","author":"Poulain","year":"2016","journal-title":"J Pain Symptom Manage"},{"key":"R53-20250731","first-page":"344","article-title":"Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations","volume":"24","author":"Hasselstrom","year":"1993","journal-title":"Clin Pharmacokinet"},{"key":"R54-20250731","doi-asserted-by":"crossref","first-page":"410","DOI":"10.2165\/00003088-199631060-00002","article-title":"Pharmacokinetics of opioids in renal dysfunction","volume":"31","author":"Davies","year":"1996","journal-title":"Clin Pharmacokinet"},{"key":"R55-20250731","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1093\/ndt\/12.12.2802","article-title":"Removal of morphine but not fentanyl during haemodialysis","volume":"12","author":"Bastani","year":"1997","journal-title":"Nephrol Dial Transpl"},{"key":"R56-20250731","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1097\/00000542-200005000-00038","article-title":"Insidious intoxication after morphine treatment in renal failure: delayed onset of morphine-6-glucuronide action","volume":"92","author":"Angst","year":"2000","journal-title":"Anesthesiology"},{"key":"R57-20250731","first-page":"701","article-title":"Narcotic analgesics in renal failure","volume":"55","author":"Fitzgerald","year":"1991","journal-title":"Conn Med"},{"key":"R58-20250731","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1681\/ASN.2006050477","article-title":"Efficacy of the World Health Organization analgesic ladder to treat pain in end-stage renal disease","volume":"17","author":"Barakzoy","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"R59-20250731","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0952-8180(95)00092-5","article-title":"The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation","volume":"8","author":"Kirvele","year":"1996","journal-title":"J Clin Anesth"},{"key":"R60-20250731","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/01.smj.0000242876.45747.0a","article-title":"Oxycodone accumulation in a hemodialysis patient","volume":"100","author":"Foral","year":"2007","journal-title":"South Med J"},{"key":"R61-20250731","doi-asserted-by":"crossref","first-page":"157","DOI":"10.5055\/jom.2015.0265","article-title":"The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy, an abuse-deterrent formulation of extended-release oxycodone, in patients with hepatic or renal impairment","volume":"11","author":"Malhotra","year":"2015","journal-title":"J Opioid Manag"},{"key":"R63-20250731","first-page":"34","article-title":"Opioid dosing in renal and hepatic impairment","volume":"39","author":"Gerlot","year":"2014","journal-title":"US Pharm"},{"key":"R64-20250731","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/ana.410130213","article-title":"Central nervous system excitatory effects of meperidine in cancer patients","volume":"13","author":"Kaiko","year":"1983","journal-title":"Ann Neurol"},{"key":"R65-20250731","first-page":"1072","article-title":"Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implications for interindividual variability in disposition, efficacy, and drug interactions","volume":"25","author":"Labroo","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"R66-20250731","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.jpainsymman.2004.02.021","article-title":"Opioids in renal failure and dialysis patients","volume":"28","author":"Dean","year":"2004","journal-title":"J Pain Sympto Manage"},{"key":"R67-20250731","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1093\/ndt\/gfl380","article-title":"Longitudinal validation of a modified Edmonton symptom assessment system (ESAS) in haemodialysis patients","volume":"21","author":"Davison","year":"2006","journal-title":"Nephrol Dial Transpl"},{"key":"R68-20250731","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jpainsymman.2009.06.002","article-title":"Establishing \u201cbest practices\u201d for opioid rotation: conclusions of an expert panel","volume":"38","author":"Fine","year":"2009","journal-title":"J Pain Symptom Manage"},{"key":"R69-20250731","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jpainsymman.2009.06.001","article-title":"Opioid rotation: the science and the limitations of the equianalgesic dose table","volume":"38","author":"Knotkova","year":"2009","journal-title":"J Pain Symptom Manage"},{"key":"R70-20250731","doi-asserted-by":"crossref","first-page":"143","DOI":"10.14336\/AD.2017.0306","article-title":"A comprehensive review of non-steroidal anti-inflammatory drug use in the elderly","volume":"9","author":"Wongrakpanich","year":"2018","journal-title":"Aging Dis"},{"key":"R71-20250731","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1093\/ndt\/gfn745","article-title":"Acetaminophen, aspirin and progression of advanced chronic kidney disease","volume":"24","author":"Evans","year":"2009","journal-title":"Nephrol Dial Transpl"},{"key":"R72-20250731","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1526-4637.2005.00072.x","article-title":"Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool","volume":"6","author":"Webster","year":"2005","journal-title":"Pain Med"},{"key":"R73-20250731","first-page":"CD004311","article-title":"Opioids for the management of breakthrough (episodic) pain in cancer patients","author":"Zeppetella","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"R74-20250731","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1177\/0269216310385601","article-title":"Opioids for the management of breakthrough cancer pain in adults: a systematic review undertaken as part of an EPCRC opioid guidelines project","volume":"25","author":"Zeppetella","year":"2011","journal-title":"Palliat Med"},{"key":"R75-20250731","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2165\/11592910-000000000-00000","article-title":"Newer generation fentanyl transmucosal products for breakthrough pain in opioid-tolerant cancer patients","volume":"31","author":"Elsner","year":"2011","journal-title":"Clin Drug Investig"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000002949","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T22:13:14Z","timestamp":1753999994000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000002949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,22]]},"references-count":69,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/dss.0000000000002949","relation":{},"ISSN":["1076-0512","1524-4725"],"issn-type":[{"value":"1076-0512","type":"print"},{"value":"1524-4725","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,22]]}}}